• March 3, 2021

Neurosense Completes Successful Phase IIA And Receives Patent Allowance

Read More

• January 12, 2021

Neurosense Granted European Orphan Drug Designation

Read More

• January 7, 2021

Neurosense’s Origins, Current Status And Plans Forward

Read More

• December 10, 2020

Neurosense Presents At ALS/MND Symposium

Read More

• November 18, 2020

Continuation Of Positive Trends In Als Clinical Trial

Read More

• September 30, 2020

Neurosense’s Clinical Trial Interim Results Webinar

Read More

• September 24, 2020

Introducing The Women Behind Neurosense

Read More

• September 9, 2020

Encouraging Interim Results Of Neurosense’s Clinical Study

Read More

• February 12, 2020

Clinical Studies Initiation And Orphan Drug Designation

Read More

• March 25, 2019

Meet Our Investors

Read More

• February 10, 2019

Read Neurosense’s Story

Read More

• January 3, 2019

Zebrafish Assist In The Battle Against ALS

Read More